Apyx Medical Corporation Announces Results of the U.S. IDE Clinical Study Evaluating the Use of Renuvion to Improve the Appearance of Lax Skin in the Neck and Submental Region
CLEARWATER, Fla.--(BUSINESS WIRE)--Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced that the results of the pivotal Phase II of its Investigational Device Exemption (“IDE”) study evaluating the safety and effectiveness of the Renuvion device to…